Company news
Urogen Pharma Ltd. (NASDAQ:URGN) news
Urogen Pharma Ltd. news releases on 6ix. Latest, Apr 26, 2025: UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION…
Press releases — page 2
UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
April 25, 2025
UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers
April 13, 2025
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
March 9, 2025
UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025
February 26, 2025
UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference
February 23, 2025
UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations
February 19, 2025
UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102
February 13, 2025
Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology
February 11, 2025
New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)
January 21, 2025
ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025
January 14, 2025
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
December 4, 2024
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
December 4, 2024
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs
December 1, 2024
New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
November 25, 2024
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
November 5, 2024
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
November 4, 2024
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024
October 29, 2024
ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
October 27, 2024
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
October 14, 2024
UroGen Appoints Chris Degnan as Chief Financial Officer
October 8, 2024
First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
October 1, 2024
UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041
September 15, 2024
UroGen Submits Completed UGN-102 NDA Seeking Approval as the First FDA-Approved Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
August 13, 2024
UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights
August 12, 2024
UroGen Pharma to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
August 4, 2024
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
June 16, 2024
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
June 16, 2024
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
June 12, 2024
UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024
June 5, 2024
UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
June 4, 2024
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
June 2, 2024
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
May 21, 2024
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
May 12, 2024
UroGen Pharma to Participate at Upcoming Investor Conferences
May 6, 2024
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
May 4, 2024
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
May 3, 2024
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
May 3, 2024
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
May 2, 2024
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
April 16, 2024
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
April 14, 2024
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
April 2, 2024
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
March 13, 2024
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
March 3, 2024
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
February 25, 2024
UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
January 23, 2024
UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers
January 16, 2024
UroGen Pharma to Participate in the B. Riley Healthcare Conference
January 10, 2024
UroGen Pharma Reports Third Quarter 2023 Financial Results
November 13, 2023
UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology
November 12, 2023
UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
November 6, 2023